| Merus: Great European Oncology Developer, But Properly Valued | 08/14 17:13 | seekingalpha.com |
| Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates | 08/01 18:31 | zacks.com |
| Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update | 08/01 16:10 | globenewswire.com |
| Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? | 07/29 11:06 | zacks.com |
| Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC | 07/24 07:00 | globenewswire.com |
| Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting | 06/03 14:30 | globenewswire.com |
| Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting | 06/02 12:30 | globenewswire.com |
| Merus Announces Pricing of Upsized Public Offering of Common Shares | 05/29 21:30 | globenewswire.com |
| Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference | 05/29 08:00 | globenewswire.com |
| Merus N.V. Announces Proposed Public Offering of Common Shares | 05/28 16:01 | globenewswire.com |